BRISTOL-MYERS SQUIBB and Celldex Therapeutics Inc. entered into a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of nivolumab, BMS’s investigational PD-1 immune checkpoint inhibitor, and varlilumab, Celldex’s CD27 targeting investigational antibody in a phase I/II study.
The NCI Human Tumor Atlas Network (HTAN) has published a cluster of papers intended to advance the framework of spatial omics, the science of profiling morphological and molecular features of human cancers in two and three dimensions.
